单位：[1]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America[2]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany[3]Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, United States of America[4]National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China[5]Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, United Kingdom[6]National Heart and Lung Institute, Imperial College London, London, United Kingdom[7]AstraZeneca, Durham, NC, United States of America[8]AstraZeneca, Morristown, NJ, United States of America[9]AstraZeneca, Gaithersburg, MD, United States of America[10]AstraZeneca, Gothenburg, Sweden
第一作者单位：[1]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America[*1]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America
通讯作者：
通讯机构：[1]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America[*1]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America
推荐引用方式(GB/T 7714)：
Martinez Fernando J.,Rabe Klaus F.,Ferguson Gary T.,et al.COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels[J].EUROPEAN RESPIRATORY JOURNAL.2020,56:doi:10.1183/13993003.congress-2020.977.
APA：
Martinez, Fernando J.,Rabe, Klaus F.,Ferguson, Gary T.,Wang, Chen,Singh, Dave...&Dorinsky, Paul.(2020).COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels.EUROPEAN RESPIRATORY JOURNAL,56,
MLA：
Martinez, Fernando J.,et al."COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels".EUROPEAN RESPIRATORY JOURNAL 56.(2020)
医学